Trial intelligence / Profile preview

MSJ-0011 vs Urinary hCG for Ovulation Induction in Japanese Women

NCT01653743Phase 3Completed

Sponsor
Merck KGaA
Start
Sep 2012
Primary completion
Nov 2014
Modality
rProtein (Recombinant Protein), Hormone, Biologic
Countries
1
01

Overview

A Phase 3 trial of choriogonadotropin alfa in anovulation, Oligo-ovulation, sponsored by Merck KGaA. Started Sep 2012; status: completed.

02

Drugs

choriogonadotropin alfa
03

Conditions

anovulationOligo-ovulation

Beyond the preview

Go deeper on NCT01653743.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01653743.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call